Intravenous magnesium therapy for moderate to severe pediatric asthma: Results of a randomized, placebo-controlled trial☆,☆☆,★
Section snippets
METHODS
This clinical trial was approved by the Children's Hospital Boston Institutional Review Board and was conducted from Sept. 20, 1993, through Dec. 20, 1994. All patients 6 to 18 years of age coming to the emergency department at Children's Hospital Boston with an acute asthma exacerbation were evaluated for the study. Peak expiratory flow rate was measured in patients who had required three nebulized β2-adrenergic treatments while in the emergency department. This measurement was performed with
RESULTS
Thirty-one patients completed the study. Mean age was 11.4 ± 3.5 years; 35% were less than 10 years old, and 45% were female. Fifteen patients were randomly assigned to the magnesium group and 16 to the placebo group. The Table illustrates that baseline demographic and clinical variables were not significantly different between the two groups on enrollment into the study, with the exception of FEV1, which was 33.1 ± 11.4 in the IVMg group and 45.1 ± 12.2 in the control group (p = 0.01).
DISCUSSION
This randomized, controlled trial of IVMg treatment demonstrates the clinical benefit in pediatric patients with moderate to severe asthma. The improvement associated with magnesium therapy was reflected in a higher percentage of improvement in PEFR, FEV1, and FVC and in a lower rate of hospital admission.
A worthwhile measure of therapeutic benefit is the number of patients who would require the intervention under study for one patient to have the outcome of interest.16 On the basis of our
Acknowledgements
We thank Dr. Gary Fleisher, the emergency medicine fellows, and the nursing staff at the Children's Hospital Boston for their assistance in the completion of this study.
References (19)
- et al.
Intravenous magnesium sulfate in the management of acute respiratory failure complicating asthma
Ann Emerg Med
(1989) - et al.
Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma
Chest
(1990) - et al.
Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization
Ann Emerg Med
(1992) - et al.
Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations
Chest
(1993) Magnesium and its therapeutic uses: a review
Am J Med
(1994)Asthma—United States, 1982-1992
MMWR Morb Mortal Wkly Rev
(1995)2000: national health promotion and disease prevention objectives—full report, with commentary
(1991)- et al.
Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma
JAMA
(1987) Blood serum magnesium in bronchial asthma and its treatment by the administration of magnesium sulphate
J Lab Clin Med
(1940)
Cited by (163)
Intravenous magnesium sulfate for asthma exacerbations in children: Systematic review with meta-analysis
2024, Paediatric Respiratory ReviewsIntravenous Magnesium for Acute Asthma Exacerbations in Children: To Mag or Not to Mag
2022, Journal of Allergy and Clinical Immunology: In PracticeMagnesium Treatment in Pediatric Patients
2021, Journal of Pediatric Health CareCitation Excerpt :A retrospective review that assessed prescribing patterns of IV magnesium for acute asthma exacerbations in pediatric patients at four hospitals found the median magnesium sulfate dose was 40 mg/kg over an average of 20 min; with doses ranging from 20 to 50 mg/kg over 20–180 min Kokotajlo, Degnan, Meyers, Siu, & Robinson, 2014). A randomized double-blinded, placebo-controlled trial by Ciarallo, Sauer & Shannon (1996) assessed 31 pediatric patients (aged 6–18 years) being treated for an acute asthma exacerbation with either magnesium sulfate or a saline solution (Ciarallo et al., 1996). Patients treated with IV magnesium sulfate were found to have greater improvement in short-term pulmonary function tests than the placebo group.
Question 5: Magnesium Sulphate for Acute Asthma in children
2020, Paediatric Respiratory ReviewsIntravenous Magnesium in Asthma Pharmacotherapy: Variability in Use in the PECARN Registry
2020, Journal of Pediatrics
- ☆
From the Division of Emergency Medicine and the Program in Clinical Pharmacology/Toxicology, Children's Hospital Boston, the Department of Pediatrics, Harvard Medical School, Boston, and the Massachusetts Poison Control System, Boston
- ☆☆
Reprint requests: Lydia Ciarallo, MD, Department of Emergency Medicine, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903.
- ★
0022-3476/96/$5.00 + 0 9/21/76427